3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
15
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Stomach Neoplasms
2
Neoplasm Metastasis
2
Carcinoma
2
Spinocerebellar Degenerations
1
Rectal Neoplasms
1
Neoplasms
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Diseases
1
Advanced Colorectal Cancer
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Fluorouracil
16
Cisplatin
11
Radiotherapy
8
Oxaliplatin
8
Leucovorin
8
Neoadjuvant Therapy
5
Capecitabine
5
Paclitaxel
4
Nivolumab
4
Docetaxel
4
Trastuzumab
3
Carboplatin
3
dehydroftorafur
2
Radiation
2
Irinotecan
2
Epirubicin
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
zolbetuximab
1
zimberelimab
1
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
pertuzumab
1
pembrolizumab
1
gastrin immunogen
1
Taxes
1
Surgical Procedures, Operative
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Adenocarcinoma Of Esophagus
×
trifluridine tipiracil drug combination
×
Clear all
NCT06356311
2026-02-27
TroFuse-015
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
450 enrolled